147 related articles for article (PubMed ID: 38022448)
1. Efficacy of Accelerated Vaccination against Hbv to Achieve Antibody formation in Multiple Sclerosis Patients Receiving Anti-Cd20 Therapy.
Koc ER; Turan OF; Saridas F; Menguc B; Minaz SN; Ozkaya G
Ann Indian Acad Neurol; 2023; 26(5):697-701. PubMed ID: 38022448
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
Buonomo AR; Viceconte G; Calabrese M; De Luca G; Tomassini V; Cavalla P; Maniscalco GT; Ferraro D; Nociti V; Radaelli M; Buscarinu MC; Paolicelli D; Gajofatto A; Annovazzi P; Pinardi F; Di Filippo M; Cordioli C; Zappulo E; Scotto R; Gentile I; Spiezia AL; Petruzzo M; De Angelis M; Brescia Morra V; Solaro C; Gasperini C; Cocco E; Moccia M; Lanzillo R;
J Neurol; 2022 Jun; 269(6):3301-3307. PubMed ID: 35165767
[TBL] [Abstract][Full Text] [Related]
3. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
[TBL] [Abstract][Full Text] [Related]
4. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
[TBL] [Abstract][Full Text] [Related]
5. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A; Mandel M; Dreyer-Alster S; Harari G; Magalashvili D; Sonis P; Dolev M; Menascu S; Flechter S; Falb R; Gurevich M
Ther Adv Neurol Disord; 2021; 14():17562864211012835. PubMed ID: 34035836
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L; Blinkenberg M; Bramow S; Papp V; Rasmussen PV; Kant M; Schäfer J; Mathiesen HK; Jensen MB; Sirakov G; Berg JM; Kopp TI; Joensen H; Sellebjerg F; Magyari M
Eur J Neurol; 2022 Feb; 29(2):496-504. PubMed ID: 34644452
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab: a new milestone in multiple sclerosis therapy.
Mulero P; Midaglia L; Montalban X
Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
[TBL] [Abstract][Full Text] [Related]
13. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
Ciardi MR; Iannetta M; Zingaropoli MA; Salpini R; Aragri M; Annecca R; Pontecorvo S; Altieri M; Russo G; Svicher V; Mastroianni CM; Vullo V
Open Forum Infect Dis; 2019 Jan; 6(1):ofy356. PubMed ID: 30697576
[TBL] [Abstract][Full Text] [Related]
15. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
16. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
Tien YC; Yen HH; Li CF; Liu MP; Hsue YT; Hung MH; Chiu YM
Arthritis Res Ther; 2018 Nov; 20(1):246. PubMed ID: 30382902
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
18. Decreased immune response to hepatitis B eight years after routine vaccination in Israel.
Gold Y; Somech R; Mandel D; Peled Y; Reif S
Acta Paediatr; 2003 Oct; 92(10):1158-62. PubMed ID: 14632331
[TBL] [Abstract][Full Text] [Related]
19. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
20. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
Azarkeivan A; Karimi G; Shaiegan M; Maghsudlu M; Tabbaroki A
Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]